On Tuesday, Adaptive Biotechnologies Corp (NASDAQ: ADPT) opened higher 0.85% from the last session, before settling in for the closing price of $10.56. Price fluctuations for ADPT have ranged from $3.22 to $10.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -1.51%. Company’s average yearly earnings per share was noted 21.47% at the time writing. With a float of $144.91 million, this company’s outstanding shares have now reached $151.92 million.
Let’s determine the extent of company efficiency that accounts for 619 employees. In terms of profitability, gross margin is 61.06%, operating margin of -71.5%, and the pretax margin is -74.86%.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adaptive Biotechnologies Corp is 4.61%, while institutional ownership is 94.92%. The most recent insider transaction that took place on May 16 ’25, was worth 17,149. In this transaction Chief Financial Officer of this company sold 1,929 shares at a rate of $8.89, taking the stock ownership to the 277,396 shares. Before that another transaction happened on May 01 ’25, when Company’s Chief Scientific Officer sold 68,412 for $7.35, making the entire transaction worth $502,828. This insider now owns 1,279,524 shares in total.
Adaptive Biotechnologies Corp (ADPT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 21.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.19% during the next five years compared to -1.51% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Check out the current performance indicators for Adaptive Biotechnologies Corp (ADPT). In the past quarter, the stock posted a quick ratio of 2.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Looking closely at Adaptive Biotechnologies Corp (NASDAQ: ADPT), its last 5-days average volume was 1.75 million, which is a drop from its year-to-date volume of 1.94 million. As of the previous 9 days, the stock’s Stochastic %D was 64.95%.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 95.23%, which indicates a significant increase from 79.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.58% in the past 14 days, which was lower than the 77.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.07, while its 200-day Moving Average is $7.05. However, in the short run, Adaptive Biotechnologies Corp’s stock first resistance to watch stands at $10.84. Second resistance stands at $11.04. The third major resistance level sits at $11.23. If the price goes on to break the first support level at $10.45, it is likely to go to the next support level at $10.26. Should the price break the second support level, the third support level stands at $10.06.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
There are currently 151,917K shares outstanding in the company with a market cap of 1.62 billion. Presently, the company’s annual sales total 178,960 K according to its annual income of -159,490 K. Last quarter, the company’s sales amounted to 52,440 K and its income totaled -29,850 K.
